JP2016535042A - ２−ベンジル−ベンゾイミダゾール補体因子ｂ阻害剤およびその使用 - Google Patents

２−ベンジル−ベンゾイミダゾール補体因子ｂ阻害剤およびその使用 Download PDF

Info

Publication number
JP2016535042A
JP2016535042A JP2016527174A JP2016527174A JP2016535042A JP 2016535042 A JP2016535042 A JP 2016535042A JP 2016527174 A JP2016527174 A JP 2016527174A JP 2016527174 A JP2016527174 A JP 2016527174A JP 2016535042 A JP2016535042 A JP 2016535042A
Authority
JP
Japan
Prior art keywords
methoxy
benzo
alkyl
imidazole
carbonitrile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2016527174A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016535042A5 (enExample
Inventor
アダムス，クリストファー
武 江原
武 江原
ジェンザ，キース
ジ，ナン
俊夫 川波
俊夫 川波
マイノルフィ，ネロ
ジェイ． パワーズ，ジェームズ
ジェイ． パワーズ，ジェームズ
セラーノ−ウー，マイケル
チャン，チュン
ガネーシュ カーキ，ラジェシュリ
ガネーシュ カーキ，ラジェシュリ
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2016535042A publication Critical patent/JP2016535042A/ja
Publication of JP2016535042A5 publication Critical patent/JP2016535042A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
JP2016527174A 2013-10-30 2014-10-29 ２−ベンジル−ベンゾイミダゾール補体因子ｂ阻害剤およびその使用 Ceased JP2016535042A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361897581P 2013-10-30 2013-10-30
US61/897,581 2013-10-30
PCT/US2014/063009 WO2015066241A1 (en) 2013-10-30 2014-10-29 2-benzyl-benzimidazole complement factor b inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
JP2016535042A true JP2016535042A (ja) 2016-11-10
JP2016535042A5 JP2016535042A5 (enExample) 2017-12-07

Family

ID=51982745

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016527174A Ceased JP2016535042A (ja) 2013-10-30 2014-10-29 ２−ベンジル−ベンゾイミダゾール補体因子ｂ阻害剤およびその使用

Country Status (5)

Country Link
US (1) US9676728B2 (enExample)
EP (1) EP3089963A1 (enExample)
JP (1) JP2016535042A (enExample)
CN (1) CN105849090A (enExample)
WO (1) WO2015066241A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021522262A (ja) * 2018-05-03 2021-08-30 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． レチノイド関連オルファン受容体ガンマ（ＲＯＲγ）のモジュレーターとしてのベンジイミダゾール誘導体およびそれらの医薬品用途
JP2022538767A (ja) * 2019-06-12 2022-09-06 ザ ウィスター インスティテュート アセチルＣｏＡシンテターゼ２（ＡＣＳＳ２）阻害剤およびそれを使用する方法

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035408A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
MX2018016046A (es) 2016-06-27 2019-05-02 Achillion Pharmaceuticals Inc Quinazolina y compuestos indol para tratar trastornos medicos.
CA3053818A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
EP3841086B1 (en) 2018-08-20 2025-04-23 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
JP7443375B2 (ja) 2018-09-06 2024-03-05 アキリオン ファーマシューティカルズ， インコーポレーテッド 医学的障害の治療のための大環状化合物
WO2020051538A1 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor d inhibitors
WO2020069024A1 (en) 2018-09-25 2020-04-02 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor d inhibitors
MX2021011507A (es) 2019-03-22 2021-12-15 Achillion Pharmaceuticals Inc Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento.
CN109942496B (zh) * 2019-04-22 2022-03-22 河南师范大学 2-(α-羟基芳基)苯并咪唑类化合物的制备方法
JP2023515073A (ja) 2020-02-20 2023-04-12 アキリオン ファーマシューティカルズ， インコーポレーテッド 補体因子ｄ媒介障害の処置用のヘテロアリール化合物
KR20230049115A (ko) 2020-08-07 2023-04-12 상하이 메이유에 바이오테크 디벨롭먼트 컴퍼니 리미티드 보체 인자 b 억제제 및 이의 약학적 조성물, 제조 방법 및 용도
CN114057692B (zh) 2020-08-07 2023-07-21 上海美悦生物科技发展有限公司 一种杂环类化合物、其制备方法及用途
CA3193488A1 (en) 2020-09-23 2022-03-31 Jason Allan Wiles Pharmaceutical compounds for the treatment of complement mediated disorders
AU2022376760A1 (en) 2021-10-27 2024-05-02 Hansoh Bio Llc Piperidinyl indole derivatives, preparation methods and medicinal uses thereof
EP4471021A4 (en) 2022-01-26 2025-04-30 Shanghai Meiyue Biotech Development Co., Ltd. Salt type and crystal form of complement factor b inhibitor, and preparation method therefor and application thereof
JP2025530222A (ja) 2022-09-10 2025-09-11 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 ２－置換ピペリジン誘導体、その製造方法及び医薬的用途
CN118026998A (zh) 2022-11-11 2024-05-14 上海医药工业研究院有限公司 哌啶取代的苯甲酸类化合物、其药物组合物和应用
AU2024261191A1 (en) 2023-04-27 2025-11-06 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Salt of piperidylindole compound and preparation method therefor
CN119371402A (zh) 2023-07-26 2025-01-28 上海美悦生物科技发展有限公司 螺环烯基类或氮杂烯基类化合物及其药物组合物、制备方法和用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6165848A (ja) * 1984-08-17 1986-04-04 ビーチヤム・グループ・ピーエルシー 新規化合物，その製法及びそれを含む医薬組成物
JP2003513041A (ja) * 1999-10-29 2003-04-08 メルク エンド カムパニー インコーポレーテッド ２−ベンジル及び２−ヘテロアリールベンズイミダゾールｎｍｄａ／ｎｒ２ｂアンタゴニスト
JP2007506687A (ja) * 2003-09-24 2007-03-22 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング キナーゼ阻害剤としての１，３−ベンゾオキサゾリル誘導体
JP2007521296A (ja) * 2003-07-01 2007-08-02 メルク　エンド　カムパニー　インコーポレーテッド 高眼圧の治療のための眼科用組成物
WO2011148956A1 (ja) * 2010-05-24 2011-12-01 トーアエイヨー株式会社 縮合イミダゾール誘導体
WO2013164802A1 (en) * 2012-05-04 2013-11-07 Novartis Ag Complement pathway modulators and uses thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859684A (en) 1986-09-15 1989-08-22 Janssen Pharmaceutica N.V. (1H-imidazol-1-ylmethyl) substituted benzimidazole derivatives and use thereof in treating androgen dependent disorders
US5342957A (en) 1988-11-29 1994-08-30 Janssen Pharmaceutica N.V. Benzimidazoles useful in treating epithelial disorders
CA2026792A1 (en) 1989-11-01 1991-05-02 Michael N. Greco (6,7-dihydro-5h-pyrrolo[1,2-c]imidazol-5-yl)- and (5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl) substituted 1h-benzotriazole derivatives
US5216018A (en) 1992-02-14 1993-06-01 Du Pont Merck Pharmaceutical Company Hydroisoindolines and hydroisoquinolines as psychotropic
FR2708609B1 (fr) 1993-07-29 1995-10-20 Sanofi Elf Dérivés de méthylguanidine, leurs procédés de préparation ainsi que les compositions en contenant.
DE69518497T2 (de) 1994-12-07 2001-04-19 Japan Science And Technology Corp., Kawaguchi Verfahren zur Herstellung eines Alkohols
GB9516943D0 (en) 1995-08-18 1995-10-18 Cancer Soc Auckland Div Nz Inc Novel cyclopropylindoles and their secoprecursors,and their use as prodrugs
WO1999040072A1 (de) 1998-02-03 1999-08-12 Boehringer Ingelheim Pharma Kg 5-gliedrige benzokondensierte heterocyclen als antithrombotika
US7338785B2 (en) 1998-12-11 2008-03-04 Clontech Laboratories, Inc. Nucleic acids encoding chromophores/fluorophores and methods for using the same
JP4362899B2 (ja) 1999-08-18 2009-11-11 カシオ計算機株式会社 データ受信装置、及び記憶媒体
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
AR043692A1 (es) 2003-02-06 2005-08-10 Novartis Ag 2-cianopirrolopirimidinas y sus usos farmaceuticos
KR20070101216A (ko) 2004-10-08 2007-10-16 쉐링 코포레이션 트롬빈 수용체 길항제
CA2597447C (en) 2005-02-14 2014-03-25 Bionomics Limited Novel tubulin polymerisation inhibitors
US20060223849A1 (en) 2005-03-14 2006-10-05 Mjalli Adnan M Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors
JP2008545663A (ja) 2005-05-27 2008-12-18 クイーンズ ユニバーシティ アット キングストン タンパク質フォールディング障害の治療
JP2009514534A (ja) 2005-11-02 2009-04-09 アメリカ合衆国 加齢黄斑変性の識別および検査のための発展した方法（ｍｅｒｔ−ａｒｍｄ）
DK2500030T4 (en) 2005-11-04 2018-10-29 Genentech Inc Use of complement pathway inhibitors for the treatment of eye diseases
GB0526258D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
US8012683B2 (en) 2006-02-13 2011-09-06 University Of Iowa Research Foundation Variants in complement regulatory genes predict age-related macular degeneration
US20080146501A1 (en) 2006-02-13 2008-06-19 University Of Iowa Research Foundation Protective complement proteins and age-related macular degeneration
EP1989319A4 (en) 2006-02-13 2009-11-11 Univ Iowa Res Found VARIANTS OF COMPLEMENTARY REGULATOR GENES AS FORECAST FOR AGE-RELATED MACULAR GENERATION
WO2007120975A2 (en) 2006-02-13 2007-10-25 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Variants in complement regulatory genes predict age-related macular degeneration
US7951829B2 (en) 2006-05-03 2011-05-31 Janssen Pharmaceutica Nv Benzimidazole modulators of VR1
WO2008003703A1 (en) 2006-07-03 2008-01-10 Biovitrum Ab (Publ) Indoles as 5-ht6 modulators
US9233106B2 (en) 2006-07-12 2016-01-12 Cornell Research Foundation, Inc. Inhibition of beta-amyloid peptide aggregation
EP2148691B1 (en) 2007-02-05 2015-05-20 Apellis Pharmaceuticals, Inc. Compstatin analogues for use in the treatment of inflammatory conditions of the respiratory system
MX2009009200A (es) 2007-03-01 2009-10-28 Advanced Vision Therapies Inc Tratamiento de enfermedades caracterizadas por la inflamacion.
JP2010526555A (ja) 2007-05-11 2010-08-05 タフツ・メディカル・センター 加齢関連黄斑変性と関係するポリヌクレオチド及び患者のリスクを評価する方法
EP2211856A4 (en) 2007-11-29 2011-02-09 Hospital For Sick Children COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL DISORDER
AU2009217317A1 (en) 2008-02-21 2009-08-27 University Of Miami Methods and compositions for diagnosis of age-related macular degeneration
JP2010031250A (ja) 2008-06-23 2010-02-12 Sumitomo Chemical Co Ltd 組成物及び該組成物を用いてなる発光素子
JP5539635B2 (ja) 2008-08-08 2014-07-02 信一郎 礒部 蛍光色素
GB0816702D0 (en) 2008-09-12 2008-10-22 Trinity College Dublin Complement proteins
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
WO2010085542A2 (en) 2009-01-23 2010-07-29 Novartis Ag Biomarkers related to age-related macular degeneration (amd)
WO2010127152A2 (en) 2009-04-29 2010-11-04 Irm Llc Compounds and compositions as microsomal prostaglandin e synthase-1 inhibitors
US20120190578A1 (en) 2009-08-06 2012-07-26 Washington University Plasma Complement Components as Expression Markers for Age-Related Macular Degeneration and Related Phenotypes
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
US9056874B2 (en) 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof
US9475806B2 (en) 2013-03-14 2016-10-25 Novartis Ag Complement factor B inhibitors and uses there of

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6165848A (ja) * 1984-08-17 1986-04-04 ビーチヤム・グループ・ピーエルシー 新規化合物，その製法及びそれを含む医薬組成物
JP2003513041A (ja) * 1999-10-29 2003-04-08 メルク エンド カムパニー インコーポレーテッド ２−ベンジル及び２−ヘテロアリールベンズイミダゾールｎｍｄａ／ｎｒ２ｂアンタゴニスト
JP2007521296A (ja) * 2003-07-01 2007-08-02 メルク　エンド　カムパニー　インコーポレーテッド 高眼圧の治療のための眼科用組成物
JP2007506687A (ja) * 2003-09-24 2007-03-22 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング キナーゼ阻害剤としての１，３−ベンゾオキサゾリル誘導体
WO2011148956A1 (ja) * 2010-05-24 2011-12-01 トーアエイヨー株式会社 縮合イミダゾール誘導体
WO2013164802A1 (en) * 2012-05-04 2013-11-07 Novartis Ag Complement pathway modulators and uses thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021522262A (ja) * 2018-05-03 2021-08-30 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． レチノイド関連オルファン受容体ガンマ（ＲＯＲγ）のモジュレーターとしてのベンジイミダゾール誘導体およびそれらの医薬品用途
JP7351851B2 (ja) 2018-05-03 2023-09-27 ジエンス ヘンルイ メデイシンカンパニー リミテッド レチノイド関連オルファン受容体ガンマ（ＲＯＲγ）のモジュレーターとしてのベンジイミダゾール誘導体およびそれらの医薬品用途
JP2022538767A (ja) * 2019-06-12 2022-09-06 ザ ウィスター インスティテュート アセチルＣｏＡシンテターゼ２（ＡＣＳＳ２）阻害剤およびそれを使用する方法

Also Published As

Publication number Publication date
EP3089963A1 (en) 2016-11-09
CN105849090A (zh) 2016-08-10
US20160311779A1 (en) 2016-10-27
WO2015066241A1 (en) 2015-05-07
US9676728B2 (en) 2017-06-13

Similar Documents

Publication Publication Date Title
JP6387391B2 (ja) 眼科疾患の処置に有用な補体因子Ｂ阻害剤としての２−（１Ｈ−インドール−４−イルメチル）−３Ｈ−イミダゾ［４，５−ｂ］ピリジン−６−カルボニトリル誘導体
US9676728B2 (en) 2-benzyl-benzimidazole complement factor B inhibitors and uses thereof
JP6238980B2 (ja) 補体経路モジュレーターおよびその使用
JP6209605B2 (ja) ピロリジン誘導体、および補体経路調節因子としてのその使用
JP6154897B2 (ja) ピロリジン誘導体、および補体経路調節因子としてのその使用
JP6378761B2 (ja) ピペリジニル−インドール誘導体および補体因子ｂ阻害剤としてのその使用
JP6163205B2 (ja) 補体経路モジュレーターおよびその使用
JP6155332B2 (ja) ピロリジン誘導体、および補体経路調節因子としてのその使用
JP6273274B2 (ja) 補体経路モジュレーターおよびその使用
JP2015522007A (ja) ピロリジン誘導体、および補体経路モジュレーターとしてのその使用
NZ715780B2 (en) Piperidinyl indole derivatives and their use as complement factor b inhibitors
NZ754317B2 (en) Piperidinyl indole derivatives and their use as complement Factor B inhibitors
NZ754317A (en) Piperidinyl indole derivatives and their use as complement Factor B inhibitors
HK1221217B (en) Piperidinyl indole derivatives and their use as complement factor b inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171024

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171024

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180626

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190222

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190327

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20190625